Clinical Trial Update: Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety and efficacy study of Vociprotafib (SAR442720) in combination with other agents for advanced cancers was terminated; results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Vociprotafib (SAR442720)

Snippet

Sponsor: Sanofi | Conditions: Metastatic Neoplasm | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-04-20